123 related articles for article (PubMed ID: 18293378)
1. Molecular evidence of the independent origin of multiple Wilms tumors in a case of WAGR syndrome.
Uccini S; Perotti D; Colarossi C; Stoppacciaro A; Sardella M; Mannarino O; Collini P; Casieri P; Cozzi D; Amoroso L; Spreafico F; Radice P; Dominici C
Pediatr Blood Cancer; 2008 Sep; 51(3):344-8. PubMed ID: 18293378
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
[TBL] [Abstract][Full Text] [Related]
3. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
4. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
Park S; Tomlinson G; Nisen P; Haber DA
Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
[TBL] [Abstract][Full Text] [Related]
5. Codon 45 of the beta-catenin gene, a specific mutational target site of Wilms' tumor.
Kusafuka T; Miao J; Kuroda S; Udatsu Y; Yoneda A
Int J Mol Med; 2002 Oct; 10(4):395-9. PubMed ID: 12239584
[TBL] [Abstract][Full Text] [Related]
6. Two molecular subgroups of Wilms' tumors with or without WT1 mutations.
Schumacher V; Schuhen S; Sonner S; Weirich A; Leuschner I; Harms D; Licht J; Roberts S; Royer-Pokora B
Clin Cancer Res; 2003 Jun; 9(6):2005-14. PubMed ID: 12796362
[TBL] [Abstract][Full Text] [Related]
7. Small glomeruli in WAGR (Wilms Tumor, Aniridia, Genitourinary Anomalies and Mental Retardation) syndrome.
Dahan K; Kamal M; Noël LH; Jeanpierre C; Gubler MC; Brousse N; Mariaud de Serre NP
Am J Kidney Dis; 2007 Jun; 49(6):793-800. PubMed ID: 17533022
[TBL] [Abstract][Full Text] [Related]
8. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
Fukuzawa R; Heathcott RW; More HE; Reeve AE
J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
[TBL] [Abstract][Full Text] [Related]
9. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
[TBL] [Abstract][Full Text] [Related]
10. Canonical WNT signalling determines lineage specificity in Wilms tumour.
Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
[TBL] [Abstract][Full Text] [Related]
11. Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome.
Baird PN; Groves N; Haber DA; Housman DE; Cowell JK
Oncogene; 1992 Nov; 7(11):2141-9. PubMed ID: 1331933
[TBL] [Abstract][Full Text] [Related]
12. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study.
Little SE; Hanks SP; King-Underwood L; Jones C; Rapley EA; Rahman N; Pritchard-Jones K
J Clin Oncol; 2004 Oct; 22(20):4140-6. PubMed ID: 15483024
[TBL] [Abstract][Full Text] [Related]
13. Familial extrarenal Wilms tumor.
Houben CH; Tong JH; Chan AW; Chik KW; Lee KH; Sihoe JD; Tam YH; Yeung CK
J Pediatr Surg; 2007 Nov; 42(11):1826-30. PubMed ID: 18022431
[TBL] [Abstract][Full Text] [Related]
14. A clinical overview of WT1 gene mutations.
Little M; Wells C
Hum Mutat; 1997; 9(3):209-25. PubMed ID: 9090524
[TBL] [Abstract][Full Text] [Related]
15. WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries?
Corbin M; de Reyniès A; Rickman DS; Berrebi D; Boccon-Gibod L; Cohen-Gogo S; Fabre M; Jaubert F; Faussillon M; Yilmaz F; Sarnacki S; Landman-Parker J; Patte C; Schleiermacher G; Antignac C; Jeanpierre C
Genes Chromosomes Cancer; 2009 Sep; 48(9):816-27. PubMed ID: 19530245
[TBL] [Abstract][Full Text] [Related]
16. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact.
Wegert J; Wittmann S; Leuschner I; Geissinger E; Graf N; Gessler M
Genes Chromosomes Cancer; 2009 Dec; 48(12):1102-11. PubMed ID: 19760609
[TBL] [Abstract][Full Text] [Related]
17. Bilateral Wilms tumor and early presentation in pediatric patients is associated with the truncation of the Wilms tumor 1 protein.
Hu M; Fletcher J; McCahon E; Catchpoole D; Zhang GY; Wang YM; Algar EM; Alexander SI
J Pediatr; 2013 Jul; 163(1):224-9. PubMed ID: 23403252
[TBL] [Abstract][Full Text] [Related]
18. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
19. Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation.
Uschkereit C; Perez N; de Torres C; Küff M; Mora J; Royer-Pokora B
J Med Genet; 2007 Jun; 44(6):393-6. PubMed ID: 17551084
[TBL] [Abstract][Full Text] [Related]
20. [WAGR syndrome by heterozygous deletion of the WT1 gene. Pediatric case report].
Galvis-Blanco SJ; Arias-Flórez JS; Contreras-García GA
Arch Argent Pediatr; 2019 Oct; 117(5):e505-e508. PubMed ID: 31560501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
